2018-11-13T08:38:46-06:00 2017-12-31 KPMG LLP 345 Park Avenue New York NY 101540102 990 2017-01-01 800631734 NEW YORK GENOME CENTER INC % NANCY KONG NEWY 6469777000 101 AVENUE OF THE AMERICAS Suite 7T NEW YORK NY 10013 ELIZABETH O'BRIEN VP & GENERAL COUNSEL 6469777000 2018-11-12 true NICOLE A FITZMAURICE P01491005 2127589700 2018-11-12 167.68.102.5 13407320183175000008 2018-11-13 P 9DD58F112FDB1D6FC5ED64343B33E2E6300E3CA8 B09A8F7452AAEB109EF01FBCB66ABFE0CB6B8889 2017 2019-02-21 02:37:17Z CHERYL A MOORE 101 AVENUE OF THE AMERICAS NEW YORK NY 10013 94913836 false X www.nygenome.org X 2010 DE NYGC IS AN INDEPENDENT, NONPROFIT ACADEMIC RESEARCH INSTITUTION DEDICATED TO ADVANCING PATIENT CARE THROUGH DISEASE-BASED GENOME RESEARCH. 25 23 232 24 855443 -192555 94901046 70723214 37095198 23716598 23269 88421 58024 95299 132077537 94623532 444802 991540 0 0 32325804 30157920 130033 140000 1231122 65312805 60996415 98213444 92285875 33864093 2337657 122070905 114196275 82869747 72657460 39201158 41538815 X OPERATE A STATE-OF-THE-ART, WORLD CLASS GENOME SEQUENCING, BIOINFORMATICS AND RESEARCH CENTER IN NEW YORK CITY. FOR MORE INFORMATION, SEE SCHEDULE O. false false 38391900 14844068 RESEARCH SEQUENCING IN 2017, NEW YORK GENOME CENTER (NYGC) SEQUENCED TENS OF THOUSANDS OF WHOLE GENOME SAMPLES, COMPLETED 780 PROJECTS, AND COLLABORATED WITH 190 INVESTIGATORS FROM 110 INSTITUTIONS WORLDWIDE. AS OF DECEMBER 2017, NYGCS HAD 5 ILLUMINA NOVASEQ INSTRUMENTS, 14 ILLUMINA HISEQ X INSTRUMENTS AND 12 ILLUMINA HISEQ 2500 INSTRUMENTS. FOR MORE INFORMATION, SEE SCHEDULE O. 24176450 991540 2350599 RESEARCH OUR RESEARCH SCIENTISTS AND FACULTY ARE EXPLORING GENOMIC CONTRIBUTORS TO HUMAN DISEASE, BOTH IN THEIR OWN PROJECTS AND THROUGH COLLABORATIONS. NYGC RESEARCHERS HAVE PROJECTS UNDERWAY IN CANCER, INCLUDING LUNG, LIVER, BREAST AND MELANOMA; NEURODEGENERATIVE DISEASES, FOCUSING ON ALS; AND AUTISM, AMONG MANY OTHERS. OUR BIOINFORMATICS SCIENTISTS PLAY A LEADERSHIP ROLE IN THE COMPLEX ANALYSIS OF DATASETS, INCLUDING INTEGRATING AND HARMONIZING CLINICAL AND GENOMIC DATA NECESSARY FOR ADVANCED RESEARCH. FOR MORE INFORMATION, SEE SCHEDULE O. 5278717 6521931 CLINICAL SEQUENCING - NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA-CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE EXOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED SANGER SEQUENCING FOR VARIANT CONFIRMATION, AND SEQUENCING OF PREPARED LIBRARIES FOR MGTL. 67847067 true true false true false false false false false false true false false true true true true false false true true false false true false false false true false true false false false false false false false false false false false false false false false false false true 73 0 true 232 true true true false false false false false false false false false X 25 23 false false false false true true true true true false false true true true true true true true true true true CT FL NJ NY OK X NANCY KONG 6469777154 101 AVENUE OF THE AMERICAS 7TH FLO NEW YORK NY 10013 X DAFNA BAR-SAGI PHD DIRECTOR 1.0 0.0 X 0 0 0 RUSSELL L CARSON MBA DIRECTOR & CO-CHAIR 4.0 0.0 X X 0 0 0 DENNIS S CHARNEY MD DIRECTOR 1.0 0.0 X 0 0 0 AUGUSTINE MK CHOI MD DIRECTOR 1.0 0.0 X 0 0 0 NICHOLAS DONOFRIO DIRECTOR 1.0 0.0 X 0 0 0 JOHN B EHRENKRANZ DIRECTOR 1.0 0.0 X 0 0 0 ANTHONY B EVNIN PHD DIRECTOR 1.0 0.0 X 0 0 0 WILLIAM E FORD DIRECTOR - THRU 02/04/17 1.0 0.0 X 0 0 0 LEE GOLDMAN MD MPH DIRECTOR 1.0 0.0 X 0 0 0 JOHN HAVENS DIRECTOR 1.0 0.0 X 0 0 0 WESLIE R JANEWAY DIRECTOR 1.0 0.0 X 0 0 0 RICHARD P LIFTON MD PHD DIRECTOR 1.0 0.0 X 0 0 0 EDISON T LIU MD DIRECTOR 1.0 0.0 X 0 0 0 HERB PARDES MD DIRECTOR & VICE CHAIR 1.0 0.0 X 0 0 0 FRANK E RICHARDSON MA JD DIRECTOR 1.0 0.0 X 0 0 0 ARTHUR J SAMBERG DIRECTOR - THRU 03/24/17 1.0 0.0 X 0 0 0 IVAN G SEIDENBERG MBA DIRECTOR & CO-CHAIR 4.0 0.0 X X 0 0 0 FRANK V SICA DIRECTOR / COMMITTEE CHAIR 1.0 0.0 X 0 0 0 JIM SIMONS PHD DIRECTOR 1.0 0.0 X 0 0 0 STEVEN SINGER ESQ DIRECTOR 1.0 0.0 X 0 0 0 ALLEN M SPIEGEL MD DIRECTOR 1.0 0.0 X 0 0 0 SAMUEL L STANLEY JR MD DIRECTOR 1.0 0.0 X 0 0 0 BRUCE STILLMAN PHD DIRECTOR 1.0 0.0 X 0 0 0 CRAIG B THOMPSON MD DIRECTOR 1.0 0.0 X 0 0 0 KEVIN J TRACEY MD DIRECTOR 1.0 0.0 X 0 0 0 TOM MANIATIS PhD DIRECTOR - INTERIM S.D. & CEO 40.0 0.0 X X 0 0 0 CHERYL A MOORE PRESIDENT & COO 40.0 0.0 X X 1167309 0 216998 CHRIS DUIGNAN VP, FINANCE 40.0 0.0 X 313374 0 42287 ELIZABETH O'BRIEN VICE PRESIDENT & GEN. COUNSEL 40.0 0.0 X 415722 0 42514 CAROL ASHE CHIEF BUSINESS OFFICER 40.0 0.0 X 451089 0 13617 HAROLD SWERDLOW PHD VP OF SEQUENCING-THRU 11/30/17 40.0 0.0 X 411959 0 28719 KATHLEEN MCGOVERN KEARNS VICE PRESIDENT, DEV'T & COMM 40.0 0.0 X 411085 0 27165 TOBY BLOOM PHD DEPUTY SCIENTIFIC DIR., INFO. 40.0 0.0 X 364761 0 30270 MATTHEW J PELO VP, FINANCIAL STRATEGY & OPS 40.0 0.0 X 322954 0 21614 SHAILAJA GARGEYA SENIOR DIR. SOFTWARE ENGINEER 40.0 0.0 X 292967 0 35830 DAYNA M OSCHWALD SNR. DIR, INFO. PGM MGMT 40.0 0.0 X 233308 0 23307 SOREN GERMER PhD DIRECTOR SEQUENCING OPERATIONS 40.0 0.0 X 205308 0 25788 TERRY DOUGLAS DONTJE SR PRINCIPAL, SOFWARE ENGINEER 40.0 0.0 X 190767 0 37156 CHRISTOPHER BLACK Director, Research Computing 40.0 0.0 X 192304 0 27715 ROBERT B DARNELL MD PHD FOUNDING DIR&CEO-THRU 12/31/16 0.0 0.0 X 463672 0 0 5436579 0 572980 87 true true false Alvarez Marsal Heathcare Industry 600 MADISON AVENUE 8TH FL NEW YORK NY 10022 Consulting Services 1490424 PJ Mechanical Service Maintenanc 55 BROAD STREET NEW YORK NY 10004 Engineering Services 612442 Gensler PO BOX 848279 DALLAS TX 75284 Architect Services 555112 Robert Darnell MD PhD 236 ELDERWOOD AVE PELHAM NY 10803 Management Services 463672 Guardian Service Industries Inc 88005 EXPEDITE WAY CHICAGO IL 60695 Cleaning Services 246979 15 3035000 21583627 46104587 70723214 RESEARCH SEQUENCING 541700 14844068 13988625 855443 RESEARCH 541700 2350599 2350599 CLINICAL SEQUENCING 541700 6521931 6521931 23716598 88421 88421 0 0 290304 290304 0 0 0 0 0 0 0 0 0 0 0 0 0 EVENT SPACE REVENUE 900099 46500 46500 OTHER REVENUE 900099 48799 48799 95299 94623532 22861155 855443 183720 991540 991540 0 0 0 4262038 2991523 1153675 116840 0 20100598 14108603 5440954 551041 1099529 771759 297627 30143 2903405 2037899 785912 79594 1792350 1258050 485164 49136 0 475009 2978 472031 174361 174361 92427 92427 140000 140000 0 3864596 2700538 1164058 91267 12079 76406 2782 773196 169011 602727 1458 2388766 1541632 846067 1067 0 15799205 10459924 5160520 178761 367132 228667 134969 3496 0 216512 108285 95427 12800 923295 696511 215027 11757 0 13063480 7501956 5516661 44863 401672 401672 DIRECT COST OF SEQUENCING 17383671 17383671 RESEARCH & CLIA 4693506 4693506 RECRUITMENT 156024 76822 79202 ALL OTHER EXPENSE 132296 112113 12799 7384 92285875 67847067 23207686 1231122 15120314 6415091 0 0 19131071 18053451 6687337 8882349 0 0 0 0 0 0 7515459 4494873 2375799 4164286 114501839 53961882 59917403 60539957 0 0 0 0 0 0 0 0 11323522 11646268 122070905 114196275 14754579 9332329 0 0 13596240 4647997 0 0 0 0 0 0 5543160 7013580 21885110 24633098 27090658 27030456 82869747 72657460 X 17485267 22459118 21715891 19079697 0 0 39201158 41538815 122070905 114196275 2337657 X false true X true true true X 14419687 52034400 61060764 94901046 70723214 293139111 0 0 14419687 52034400 61060764 94901046 70723214 293139111 96058584 197080527 83412 556550 268801 302728 378725 1590216 0 116870 58024 95299 270193 294999520 90418270 0.66807 0.70161 X false true false false false false true 3500 false true 92427 95927 false LOBBYING ACTIVITIES SCHEDULE C, PART II-B, LINES 1G & 1I THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES AT THE STATE AND LOCAL LEVEL FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. NYGC ALSO MAINTAINS MEMBERSHIPS IN SEVERAL IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE MEDICAL RESEARCH COMMUNITY; $2,427 OF THE DUES THAT NYGC PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING IN 2017. ADDITIONALLY, NYGC STAFF MAY, FROM TIME TO TIME, CONTACT FEDERAL LEGISLATORS OR THEIR STAFFS TO ENCOURAGE THEIR SUPPORT FOR MATTERS OF CONCERN TO THE ACADEMIC MEDICAL RESEARCH COMMUNITY. SUCH CONTACT MAY INCLUDE WRITING LETTERS OR OCCASIONAL MEETINGS WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH COMMUNICATIONS WITH CAPITOL HILL IS $3,500. 53507688 11826254 41681434 32444083 24951639 7492444 28550068 17183989 11366079 60539957 SECURITY DEPOSITS 11110521 DEFERRED COMPENSATION 535747 11646268 0 ACCRUED INTEREST PAYABLE 13077 DEFERRED RENT 27017379 27030456 X 94913836 94913836 -290304 -290304 94623532 92576179 290304 290304 92285875 92285875 INCOME TAXES SCHEDULE D, PART X, LINE 2 NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2017 AND 2016. REVENUE AND EXPENSE RECONCILIATION SCHEDULE D, PART XI, LINE 4B AND PART XII, LINE 2D ($290,304) RENTAL EXPENSES ALLOCABLE TO 990, PART VIII Europe (Including Iceland and Greenland) 6 Program Services RESEARCH 417871 North America 1 Program Services RESEARCH 27320 Middle East and North Africa 1 Program Services RESEARCH 22000 8 8 467191 467191 false false false false false false accounting method SCHEDULE F, PART I, LINE 3 THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD. X true COMMUNITY COUNSELLING SERVICE CAMPAIGN SERVICES false 0 140000 -140000 0 140000 -140000 CT FL NJ NY OK Schedule G, Part I, Line 2b COMMUNITY COUNSELLING SERVICE'S ADDRESS: 527 MADISON AVENUE 5TH FLOOR NEW YORK, NY 10022 SCHEDULE G, PART I, LINE 2B, COLUMN (IV) NYGC UTILIZES THE SERVICES OF A FUNDRAISING ADVISOR TO CONSULT ON THE DEVELOPMENT ACTIVITIES OF THE ORGANIZATION. DUE TO THE NATURE OF THESE ARRANGEMENTS, NYGC IS UNABLE TO REASONABLY DETERMINE THE GROSS RECEIPTS FROM THE FUNDRAISING ACTIVITIES WHICH ARE SOLELY ATTRIBUTABLE TO THIS ADVISOR. true TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NY 630 W 168TH ST NEW YORK NY 10032 135598093 501(C)(3) 196297 RESEARCH SUBAWARD COLD SPRING HARBOR LABORATORY 1 BUNGTOWN RD COLD SPRING HARBOR NY 11724 112013303 501(C)(3) 232552 RESEARCH SUBAWARD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PL BOX 1075 NEW YORK NY 10029 136171197 501(C)(3) 55874 RESEARCH SUBAWARD REGENTS OF THE UNIVERSITY OF CALIFORNIA-SF 1550 4TH STREET SAN FRANCISCO CA 94158 946036493 115 - CA 20816 RESEARCH SUBAWARD REGENTS OF THE UNIVERSITY OF CALIFORNIA-LA 11000 KINROSS AVE LOS ANGELES CA 90095 956006143 115 - CA 43901 RESEARCH SUBAWARD UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE SEATTLE WA 98195 916001537 115 - WA 196282 RESEARCH SUBAWARD THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10064 131624158 501(C)(3) 245818 RESEARCH SUBAWARD 7 MONITORING USE OF GRANT FUNDS SCHEDULE I, PART I, LINE 2 NYGC MONITORS SUBRECIPIENTS' USE OF GRANT FUNDS IN BOTH THE PRE-AWARD AND POST-AWARD STAGES. IN THE PRE-AWARD PHASE, SUBRECIPIENTS ARE EVALUATED BY NYGC'S SPONSORED RESEARCH AND ACADEMIC/SCIENTIFIC DEPARTMENTS, WITH CONSIDERATION OF SUBRECIPIENT CAPABILITIES AND INFRASTRUCTURE, AS WELL AS THE APPROPRIATE CHECKS FOR SUSPENSION AND DEBARMENT. A SUB-RECIPIENT MONITORING FORM IS SENT TO ALL SUB-AWARDEES AND THIS FORM IS THE BASIS BY WHICH NYGC ASSESSES RISK. IN THE POST-AWARD PHASE, NYGC'S GRANTS ACCOUNTING DEPARTMENT WORKS WITH THE SPONSORED RESEARCH TEAM TO MONITOR PROGRAMMATIC PROGRESS IN A MANNER CONSISTENT WITH THE TERMS AND CONDITIONS OF THE AWARD. NYGC'S FINANCE/GRANTS ACCOUNTING DEPARTMENT REVIEWS ANY SUBRECIPIENT EXPENSES INVOICED TO NYGC FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES AND BUDGETARY RESTRICTIONS AND PROVIDES SUBRECIPIENT INVOICES TO SPONSORED RESEARCH FOR ITS REVIEW AND APPROVAL. AFTER THE SPONSORED RESEARCH AND FINANCE/GRANTS ACCOUNTING DEPARTMENTS HAVE APPROVED SUBRECIPIENT INVOICES, THE SUBRECIPIENT IS PAID. SUBAWARDS ELIGIBLE FOR FFATA REPORTING ARE RECORDED IN THE FSRS (THE FFATA SUBAWARD REPORTING SYSTEM) IN ACCORDANCE WITH THE FEDERAL REPORTING REQUIREMENTS FOR FIRST-TIER SUBAWARDS UNDER NYGC'S PRIME FEDERAL AWARDS. X X true true X X X X X false true false false false false false false false ROBERT B DARNELL MD PHD FOUNDING DIR&CEO-THRU 12/31/16 136374 0 0 0 327298 0 0 0 0 0 463672 0 0 0 CHERYL A MOORE PRESIDENT & COO 897254 0 0 0 270055 0 213500 0 3498 0 1384307 0 0 0 CHRIS DUIGNAN VP, FINANCE 313374 0 0 0 0 0 12948 0 29339 0 355661 0 0 0 CAROL ASHE CHIEF BUSINESS OFFICER 431599 0 0 0 19490 0 13500 0 117 0 464706 0 0 0 HAROLD SWERDLOW PHD VP OF SEQUENCING-THRU 11/30/17 387121 0 0 0 24838 0 13500 0 15219 0 440678 0 0 0 KATHLEEN MCGOVERN KEARNS VICE PRESIDENT, DEV'T & COMM 391973 0 0 0 19112 0 10395 0 16770 0 438250 0 0 0 TOBY BLOOM PHD DEPUTY SCIENTIFIC DIR., INFO. 364761 0 0 0 0 0 13500 0 16770 0 395031 0 0 0 MATTHEW J PELO VP, FINANCIAL STRATEGY & OPS 322954 0 0 0 0 0 12899 0 8715 0 344568 0 0 0 ELIZABETH O'BRIEN VICE PRESIDENT & GEN. COUNSEL 379925 0 0 0 35797 0 13926 0 28588 0 458236 0 0 0 SHAILAJA GARGEYA SENIOR DIR. SOFTWARE ENGINEER 292967 0 0 0 0 0 13500 0 22330 0 328797 0 0 0 DAYNA M OSCHWALD SNR. DIR, INFO. PGM MGMT 233308 0 0 0 0 0 7661 0 15646 0 256615 0 0 0 SOREN GERMER PhD DIRECTOR SEQUENCING OPERATIONS 205308 0 0 0 0 0 10444 0 15344 0 231096 0 0 0 TERRY DOUGLAS DONTJE SR PRINCIPAL, SOFWARE ENGINEER 190767 0 0 0 0 0 9948 0 27208 0 227923 0 0 0 CHRISTOPHER BLACK Director, Research Computing 192304 0 0 0 0 0 9865 0 17850 0 220019 0 0 0 SCHEDULE J, PART I, LINE 1 TAX INDEMNIFICATION AND GROSS-UP PAYMENTS NYGC PROVIDED TUITION ASSISTANCE FOR A FAMILY MEMBER OF THE VICE PRESIDENT AND GENERAL COUNSEL. THE VALUE OF THIS ASSISTANCE WAS TREATED AS COMPENSATION TO THE EMPLOYEE FOR WHICH NYGC MADE GROSS-UP PAYMENTS TO ALLEVIATE THE TAX BURDEN ON THE EMPLOYEE. HOUSING ALLOWANCE OR RESIDENCE FOR PERSONAL USE NYGC PROVIDED A HOUSING ALLOWANCE TO THE PRESIDENT AND COO. THE VALUE OF THIS ASSISTANCE WAS TREATED AS TAXABLE COMPENSATION TO THE EMPLOYEE. NYGC SELECTIVELY OFFERS HOUSING ALLOWANCES TO EMPLOYEES, PRINCIPALLY AS A RECRUITING TOOL FOR NEW FACULTY AND POSTDOCTORAL FELLOWS. SUBSIDIZED HOUSING OR HOUSING ALLOWANCES ARE COMMONLY OFFERED BY PEER ACADEMIC INSTITUTIONS IN NEW YORK CITY TO HELP FACULTY AND OTHER RESEARCHERS DEFRAY THE HIGH COST OF HOUSING. EXECUTIVE COMPENSATION SCHEDULE J, PART I, LINE 3 AT THE TIME OF HIRE, AN AD-HOC EXECUTIVE COMPENSATION COMMITTEE COMPRISED OF INDEPENDENT BOARD MEMBERS (THE "AD-HOC COMMITTEE") WAS RESPONSIBLE FOR ESTABLISHING THE PRESIDENT AND COOS COMPENSATION PACKAGE AND THE TERMS OF HER EMPLOYMENT CONTRACT. HER COMPENSATION WAS DETERMINED THROUGH A REVIEW OF FORM 990 RETURNS AND COMPENSATION INFORMATION FOR TOP MANAGEMENT OFFICIALS AT SIMILARLY SITUATED ORGANIZATIONS OBTAINED THROUGH THE RECRUITING PROCESS. CONSIDERATION ALSO WAS GIVEN TO HER THEN-CURRENT COMPENSATION. ON RECOMMENDATION OF THE AD-HOC COMMITTEE, THE BOARD OF DIRECTORS APPROVED HER COMPENSATION. THIS APPROVAL WAS MEMORALIZED IN THE BOARD MINUTES. THE "INITIAL CONTRACT" EXCEPTION APPLIED FOR 2016 AND HER COMPENSATION HAS NOT CHANGED SINCE SHE JOINED NYGC. IN LATE 2016, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO REVIEW THE COMPENSATION PAID TO SENIOR MANAGEMENT. IN EARLY 2017, THE RESULTS OF THIS REVIEW WERE PROVIDED TO THE AD-HOC EXECUTIVE COMPENSATION COMMITTEE COMPRISED OF INDEPENDENT BOARD MEMBERS. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF EXECUTIVE AND SENIOR MANAGEMENT WAS REASONABLE AND THIS WAS MEMORALIZED IN THE AD-HOC COMMITTEE'S MINUTES. SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN SCHEDULE J, PART I, LINE 4B NYGC HAS A DEFERRED COMPENSATION PLAN FOR THE PRESIDENT AND COO. $200,000 WAS DEFERRED IN 2017. THE ORGANIZATIONS MISSION FORM 990, PART I, LINE 1 & PART III, LINE 1: THE NEW YORK GENOME CENTER (NYGC) IS ORGANIZED AND OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION, DEDICATED TO STATE-OF-THE-ART, WORLD CLASS GENOMIC RESEARCH, SEQUENCING AND BIOINFORMATICS, WHOSE MEMBERS INCLUDE LEADING ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) FOSTERING INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY; (II) RECRUITING AND RETAINING WORLD CLASS SCIENTIFIC TALENT TO LEAD THE SCIENTIFIC DEVELOPMENT OF THE ORGANIZATION; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGCS SCIENTIFIC PROGRAM AND GENOMIC RESEARCH; (IV) DEVELOPING ADVANCED BIOINFORMATICS CAPABILITIES BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATIONS FACILITIES; (V) ADVANCING RESEARCH TO SUPPORT THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS TO TREAT HUMAN DISEASE; (VI) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; AND (VII) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. PROGRAM SERVICE ACCOMPLISHMENTS FORM 990, PART III, LINE 4A, LINE 4B, LINE 4C NYGC IS AN INDEPENDENT, NONPROFIT ACADEMIC RESEARCH INSTITUTION WITH THE MISSION OF ADVANCING CLINICAL CARE THROUGH TRANSFORMATIVE GENOMIC RESEARCH. NYGCS WORK BUILDS ON THE STRENGTHS AND CAPABILITIES THAT THE CENTER HAS DEVELOPED SINCE ITS FOUNDING IN 2010 AND AUGMENTS RESEARCH BEING CONDUCTED BY NYGC MEMBER INSTITUTIONS. COLLABORATING WITH PREMIER ACADEMIC, MEDICAL AND INDUSTRY LEADERS ACROSS THE GLOBE, NYGC IS CONDUCTING DISEASE-BASED GENOMIC RESEARCH IN AREAS WHERE IT HAS DEVELOPED A SIGNIFICANT AND SUCCESSFUL TRACK RECORD, INCLUDING NEURODEGENERATIVE DISEASES SUCH AS ALS, NEUROPSYCHIATRIC DISEASES, PARTICULARLY AUTISM, AND CANCER, AMONG OTHERS. THROUGH GROUNDBREAKING RESEARCH, NYGCS GOAL IS TO ADVANCE THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS THAT TREAT HUMAN DISEASE. NYGC AND ITS MEMBER INSTITUTIONS AND PARTNERS ARE UNITED IN THIS UNPRECEDENTED COLLABORATION OF TECHNOLOGY, SCIENCE AND MEDICINE, DESIGNED TO HARNESS THE POWER OF INNOVATION AND DISCOVERIES TO ADVANCE GENOMIC DISCOVERIES. THEIR SHARED OBJECTIVE IS THE ACCELERATION OF MEDICAL GENOMICS AND PRECISION MEDICINE TO BENEFIT PATIENTS AROUND THE WORLD. NYGCS INNOVATION, RESEARCH AND QUALITY MAKE IT A UNIQUE AND STRONG COLLABORATIVE PARTNER. 2017 WAS A PIVOTAL YEAR FOR NYGC, POSITIONING THE ORGANIZATION FOR ITS NEXT PHASE OF GROWTH. NYGCS AWARD-WINNING FACULTY AND STAFF SCIENTISTS ARE PERFORMING THE HIGHEST QUALITY BIOINFORMATICS ANALYSIS AND DEVELOPING INNOVATIVE OPEN-SOURCE GENOMICS METHODS AND TOOLS TO SHARE WITH THE SCIENTIFIC COMMUNITY. THEY ARE LEADING THE WAY IN SINGLE-CELL ANALYSIS, GENE EDITING AND EXPLORATION OF THE NON-CODING AREA OF THE HUMAN GENOME ALL PROMISING FRONTIERS OF GENOMIC RESEARCH. IN 2017, NYGC ESTABLISHED A NEW AFFILIATE MEMBERSHIP PROGRAM, OPEN TO ALL EXTERNAL ACADEMIC RESEARCHERS, TO FURTHER ENCOURAGE THE EXCHANGE OF IDEAS AND FACILITATE MORE COLLABORATIONS. RESEARCH SEQUENCING NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE LAST FIVE YEARS, NYGCS SEQUENCING LABORATORY HAS SEQUENCED TENS OF THOUSANDS OF WHOLE GENOME SAMPLES. IN 2017, THE CENTER ACQUIRED NOVASEQ SYSTEMS SEQUENCERS TO SUPPLEMENT ITS STABLE OF HISEQ X AND 2500 SEQUENCERS. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREATER SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. RESEARCH AND FACULTY SINCE ITS INCEPTION, NYGC HAS ATTRACTED WORLD-CLASS SCIENTISTS WHOSE GENOMIC EXPERTISE INCLUDING SINGLE CELL GENOMICS, GENOME ENGINEERING, POPULATION AND EVOLUTIONARY GENOMICS, TECHNOLOGY AND METHODS DEVELOPMENT, STATISTICS, COMPUTATIONAL BIOLOGY AND BIOENGINEERING BRINGS A MULTIDISCIPLINARY AND IN-DEPTH APPROACH TO THE EVOLVING FIELD OF GENOMICS. NYGCS FACULTY SUPPORT THE SCIENTIFIC VISION OF THE CENTER THROUGH THE ADVANCEMENT OF GENOMIC MEDICINE. TO ENHANCE COLLABORATION, FACULTY MEMBERS HAVE JOINT APPOINTMENTS AT OUR INSTITUTIONAL FOUNDING MEMBERS TO STRENGTHEN OUR RESEARCH CAPABILITIES, ADVANCE ACADEMIC LEADERSHIP, AND ENHANCE THEIR ABILITY TO HELP SOLVE HUMAN DISEASES. OVER THE COURSE OF 2017, NYGC MANAGED 37 ACTIVE GRANTS, INCLUDING 22 GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH). NYGCS RESEARCHERS ARE WORKING WITH ITS MEMBER INSTITUTIONS AND AN ARRAY OF COLLABORATIVE PARTNERS TO ADDRESS THE FUNDAMENTAL CHALLENGE IN PRECISION MEDICINE: UNDERSTANDING THE RELATIONSHIP BETWEEN DNA SEQUENCE VARIATION AND MECHANISMS FOR HUMAN DISEASES, RANGING FROM CANCER TO AUTISM AND NEURODEGENERATIVE DISEASE. NYGC RESEARCHERS PUBLISHED MORE THAN 50 STUDIES IN LEADING SCIENTIFIC JOURNALS IN 2017, FUELING MOMENTUM FOR IMPORTANT COLLABORATIVE WORK. THEY COMPLETED MORE THAN 780 PROJECTS, COLLABORATING WITH 190 INVESTIGATORS FROM 110 INSTITUTIONS ACROSS THE GLOBE. OUR CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASES ALS CONSORTIUM, LED BY HEMALI PHATNANI, PHD, HAD AT THE END OF 2017 26 MEMBERS FROM LEADING INSTITUTIONS AROUND THE WORLD. SCIENTISTS AND CLINICIANS WORK COLLABORATIVELY TO APPLY STATE-OF-THE-ART CLINICAL AND FUNCTIONAL GENOMICS TOGETHER WITH BIOINFORMATICS TO STUDY ALS DISEASE MECHANISMS AND BETTER UNDERSTAND HOW MUTATIONS UNDERLYING ALS CAUSE DISEASE. THE TARGET OF THIS GLOBAL MULTIDISCIPLINARY EFFORT IS WHOLE GENOME SEQUENCING AND ANALYSIS OF 5,000 CLINICALLY WELL-ANNOTATED ALS SAMPLES BY 2021 TO ENHANCE EARLY DIAGNOSIS AND EFFECTIVE DRUG DISCOVERY. TO ADVANCE COLLABORATIVE EFFORTS ON CANCER GENOMICS, NOBEL LAUREATE HAROLD VARMUS, MD, SENIOR ASSOCIATE CORE MEMBER, NYGC, AND LEWIS THOMAS UNIVERSITY PROFESSOR OF MEDICINE, WEILL CORNELL MEDICINE, ESTABLISHED THE NEW YORK CANCER GENOMICS RESEARCH NETWORK. IN 2017, DR. VARMUS CONVENED MONTHLY MEETINGS AT NYGC WITH LEADING CANCER RESEARCHERS AND CLINICIANS FROM NYGCS INSTITUTIONAL FOUNDING MEMBERS AND OTHER KEY ACADEMIC INSTITUTIONS FROM AROUND THE WORLD. THE OBJECTIVE OF THIS MULTIDISCIPLINARY APPROACH WAS TO HELP SET CRITICAL PRIORITIES IN TRANSLATING GENOMIC SCIENCE INTO MORE EFFECTIVE TREATMENT OPTIONS FOR ALL CANCER PATIENTS IN NEW YORK AND BEYOND. THE CONSORTIUM INITIATED A CITY-WIDE PROJECT TO ENSURE THAT ADVANCES IN GENOMICS AND PRECISION MEDICINE CAN BE APPLIED TO ALL POPULATIONS AND EXPAND KNOWLEDGE OF THE GENETIC VARIATIONS THAT CONTRIBUTE TO CANCER. NAMED THE "POLYETHNIC-1000", THE PROJECT PLANS TO UTILIZE THE GREATER NEW YORK AREAS ETHNIC DIVERSITY TO ADDRESS SEVERAL IMPORTANT SCIENTIFIC QUESTIONS ABOUT THE ROLE OF ETHNICITY IN ONCOLOGY AND OFFER GENOMIC SERVICES DURING THE PROVISION OF CANCER CARE TO ALL POPULATIONS. THIS INITIATIVE WILL INVOLVE PATIENTS AND STAFF AT SEVERAL ACADEMIC HEALTH CENTERS AND PARTNER HOSPITALS IN THE NEW YORK CITY REGION AND WILL USE NYGCS GENOMICS AND INFORMATICS CAPABILITIES TO DETERMINE HOW INHERITED AND ACQUIRED GENETIC VARIATIONS AFFECT THE BEHAVIOR OF DIFFERENT CANCERS OCCURRING IN ETHNICALLY DIVERSE POPULATIONS. IN EARLY 2017, A STUDY BY NYGC CORE FACULTY MEMBER MARCIN IMIELINSKI, MD, PHD PUBLISHED IN CELL ILLUMINATED A POSSIBLE NEW TYPE OF DRIVER OF CANCER: SMALL (ONE- TO 50-LETTER) INSERTIONS OR DELETIONS OF DNA SEQUENCE, ALSO CALLED INDELS, IN REGIONS OF THE GENOME THAT DO NOT CODE FOR PROTEIN. THIS GENETIC MUTATION, WHICH OCCURS FREQUENTLY IN CANCER CELLS, MAY PROVIDE CLUES ABOUT THE DISEASES ORIGINS AND SERVE AS A BIOMARKER TO IMPROVE DIAGNOSIS AND TREATMENT. LATER IN THE YEAR, HE RECEIVED A CLINICAL SCIENTIST DEVELOPMENT AWARD FROM THE DORIS DUKE CHARITABLE FOUNDATION TO FUND HIS INVESTIGATION INTO UNDERSTANDING CANCER DRIVERS IN NON-CODING DNA THE 98 PERCENT OF THE GENOME THAT IS NOT TYPICALLY PROFILED IN STANDARD CLINICAL SEQUENCING TESTS. THE RESEARCH COULD REVEAL A NEW CLASS OF GENETIC MUTATIONS THAT DRIVE CANCER AND RESPONSE TO THERAPY. NYGC CORE FACULTY MEMBER NEVILLE SANJANA, PHD RECEIVED A SIDNEY KIMMEL FOUNDATION SCHOLAR AWARD AND A YOUNG INVESTIGATOR AWARD FROM THE MELANOMA RESEARCH ALLIANCE. THESE PRESTIGIOUS AWARDS FUND THE SANJANA LABORATORYS WORK IN LEVERAGING THE GENE-EDITING TOOL CRISPR TO COMPREHENSIVELY SURVEY MUTATIONS THAT ALLOW CANCER CELLS TO RESIST IMMUNOTHERAPY TREATMENT. NYGC CORE FACULTY MEMBER TUULI LAPPALAINEN, PHD RECEIVED A RESEARCH GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TO FUND A STUDY TO BETTER UNDERSTAND VARIABLE PENETRANCE, A PHENOMENON WHERE THE SEVERITY OF THE EFFECT OF DISEASE-CAUSING GENETIC VARIANTS DIFFERS AMONG INDIVIDUALS WHO CARRY THEM. IN OCTOBER 2017, THE CHAN ZUCKERBERG INITIATIVE (CZI) AWARDED NYGC SCIENTISTS (TECHNOLOGY INNOVATION LABORATORY MANAGER PETER SMIBERT, PHD AND CORE FACULTY MEMBER RAHUL SATIJA, PHD, CO-PRINCIPAL INVESTIGATORS) A ONE-YEAR PILOT GRANT TO DEVELOP AN OPEN-SOURCE TOOLKIT FOR CITE-SEQ, THE SINGLE-CELL GENOMICS TOOL THAT WAS DEVELOPED BY NYGCS TECHNOLOGY INNOVATION LABORATORY EARLIER IN 2017. CITE-SEQ SIMULTANEOUSLY MEASURES PROTEIN AND RNA LEVELS IN THE LARGEST SCALE DEMONSTRATION OF MULTIDIMENSIONAL SINGLE-CELL ANALYSIS TO DATE. THE AWARD, FROM THE CZI DONOR-ADVISED FUND, AN ADVISED FUND OF THE SILICON VALLEY COMMUNITY FOUNDATION, WILL ENABLE RESEARCHERS TO LEVERAGE THIS POWERFUL TOOL FOR THE HUMAN CELL ATLAS PROJECT, THE INTERNATIONAL COLLABORATIVE EFFORT TO CREATE A COMPREHENSIVE REFERENCE MAP OF ALL HUMAN CELLS. PRIOR TO THE RECEIPT OF THE CZI GRANT, IN JULY 2017, NYGC SCIENTISTS PUBLISHED THEIR STUDY AND A DESCRIPTION OF CITE-SEQ IN NATURE METHODS. CITE-SEQ REPRESENTS AN IMPORTANT STEP FORWARD FOR SINGLE-CELL RNA SEQUENCING, AN ADVANCING FIELD OF GENOMICS THAT PROVIDES DETAILED INSIGHTS INTO INDIVIDUAL CELLS AND ENABLES RESEARCHERS TO DISTINGUISH BETWEEN DIFFERENT CELL TYPES AND TO STUDY DISEASE MECHANISMS AT THE LEVEL OF INDIVIDUAL CELLS. IN SEPTEMBER 2017, CELL PUBLISHED THE RESULTS OF A LARGE-SCALE WHOLE GENOME SEQUENCING STUDY AT NYGC THAT COMPARED THE WHOLE GENOMES OF 516 AUTISTIC CHILDREN WITH NO FAMILY HISTORY OF AUTISM WITH THE WHOLE GENOMES OF THEIR PARENTS AND AN UNAFFECTED SIBLING (2,064 PEOPLE IN TOTAL). RISK-RAISING MUTATIONS, WHICH OCCURRED IN CHILDREN BUT NOT THEIR PARENTS, WERE FOUND IN BOTH PROTEIN-CODING AND REGULATORY OR NON-CODING PORTIONS OF THE GENOME. THE STUDYS FINDINGS COULD HELP RESEARCHERS BETTER UNDERSTAND THE GENETIC SIGNATURES OF AUTISM, I.E., THE SUITE OF GENETIC ABNORMALITIES UNDERLYING THE DISORDER. THE RESEARCH WAS FUNDED BY A GRANT FROM THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE, A DIVISION OF NIH, THAT ESTABLISHED NYGC AS A CENTER FOR COMMON DISEASE GENOMICS IN 2016. BIOINFORMATICS AND DATA MANAGEMENT NYGCS BIOINFORMATICS SCIENTISTS PLAY A LEADERSHIP ROLE IN THE COMPLEX ANALYSIS OF MULTIPLE DATASETS, INCLUDING INTEGRATING AND HARMONIZING CLINICAL AND GENOMIC DATA. NYGCS TEAM OF BIOINFORMATICIANS HAS EXPERTISE IN CANCER GENOMICS, STATISTICAL AND POPULATION GENETICS, EXPRESSION ANALYSIS, EPIGENOMICS AND FUNCTIONAL GENOMICS, TO NAME JUST A FEW. THEY DEVELOP, MAINTAIN AND IMPROVE DATA ANALYSIS PIPELINES BY LEVERAGING THE LARGE AMOUNTS OF SEQUENCING DATA PRODUCED AT THE CENTER. THEY WORK ON ESTIMATING THE SOURCES OF ERRORS AND VARIABILITY IN THE DATA, DEFINING METHODS TO CORRECT THEM, BOTH COMPUTATIONALLY AND ON THE LABORATORY SIDE. THEY ARE CONTINUALLY EVALUATING AND BENCHMARKING AVAILABLE TOOLS, REFINING BEST PRACTICES TO ANALYZE AND COMBINE RESULTS, AND ARE DEVELOPING NOVEL TOOLS AND METHODS FOR USE BY SCIENTISTS AROUND THE WORLD. IN 2017, OUR BIOINFORMATICS TEAM CONDUCTED AN ARRAY OF INVESTIGATIONS, INCLUDING RESEARCH ON HUMAN BRAIN DEVELOPMENT, RENAL CELL CARCINOMA, AUTISM AND BREAST CANCER. TECHNOLOGY INNOVATION TODAY, THERE ARE NUMEROUS EXCITING CLINICAL USES FOR GENOMIC INFORMATION, YET SUCH INFORMATION HAS TO BE GENERATED AND INTERPRETED IN A TIMELY, SCALABLE, AND HIGH-QUALITY FASHION IN ORDER TO SPEED AND IMPROVE THE DELIVERY OF RESULTS TO RESEARCHERS AND CLINICIANS. THE NYGC TECHNOLOGY INNOVATION LABORATORY IS A CREATIVE, MULTIDISCIPLINARY HUB WHERE SCIENTISTS ARE DEVELOPING CUTTING-EDGE TECHNOLOGIES TO ADVANCE GENOMICS RESEARCH AND CLINICAL APPLICATIONS, PARTICULARLY FOR CANCER RESEARCHERS AND CLINICIANS. THE TECHNOLOGY INNOVATION LABORATORY IS DEDICATED TO GENERATING NEW TECHNOLOGIES, PROTOCOL DEVELOPMENT, EQUIPMENT EVALUATION, AND INFORMATICS TOOL DEVELOPMENT/INTEGRATION. NYGC SCIENTISTS ARE DEVELOPING VARIOUS NOVEL TECHNOLOGIES TO SPEED UP, REDUCE COSTS OF AND DECREASE THE HANDLING OF NEXT-GENERATION LIBRARY PREPARATION REACTIONS. EDUCATION IN SUMMER 2017, NYGC COLLABORATED WITH THE NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION TO HOST A "GENOMICS HACKATHON." RESEARCHERS FROM NEW YORK CITY-AREA INSTITUTIONS AND BEYOND GATHERED AT NYGC TO TAKE PART IN A "SPRINT-LIKE" COLLABORATIVE WORKSHOP WHEREBY PARTICIPANTS INTENSIVELY WORKED TOGETHER ON COMPUTATIONAL PROJECTS RELATED TO GENOMICS AND CLINICAL RESEARCH. OVER A DOZEN TEAMS ASSEMBLED TO BRAINSTORM CREATION OF BIOINFORMATIC SOFTWARE, TOOLS FOR THE STUDY OF PROTEINS AND CANCER GENOMICS, AND PIPELINES TO ANALYZE LARGE-SCALE GENOMIC DATASETS. IN FALL 2017, NYGC LAUNCHED "GENOMIC INNOVATION," A 14-WEEK PROJECT-FOCUSED COURSE DEVELOPED BY NYGC CORE FACULTY MEMBERS NEVILLE SANJANA, PHD AND TUULI LAPPALAINEN, PHD. THE FOUR-CREDIT CLASS, THE FIRST-EVER GRADUATE-LEVEL COURSE TO BE HOSTED BY NYGC, INTRODUCED STUDENTS TO CUTTING-EDGE TECHNOLOGIES AND APPLICATIONS IN GENETICS AND GENOMICS AND THEIR RESPONSIBLE USE IN SCIENCE AND SOCIETY. GRADUATE STUDENTS FROM COLD SPRING HARBOR LABORATORY, COLUMBIA UNIVERSITY, ALBERT EINSTEIN COLLEGE OF MEDICINE, MOUNT SINAI SCHOOL OF MEDICINE (MSSM), MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC), NEW YORK UNIVERSITY (NYU), THE ROCKEFELLER UNIVERSITY, STONY BROOK UNIVERSITY AND WEILL CORNELL MEDICINE (WCM) COULD RECEIVE CREDIT FOR THE CLASS THROUGH THEIR REGISTRARS OFFICE AND THE COURSE WAS OFFICIALLY LISTED IN THE COURSE CATALOGS OF COLUMBIA, NYU, AND EINSTEIN. THE FIRST CLASS INCLUDED STUDENTS FROM COLUMBIA, EINSTEIN, MSKCC, NYU, MSSM AND WCM. AS PART OF NYGCS EDUCATIONAL MISSION, THE CENTER HOSTED MANY SCIENTIFIC MEETINGS, WORKSHOPS, CONFERENCES AND LECTURES IN 2017. NYGC HELD "EVENING TALKS," A LECTURE SERIES FOR THE GENERAL PUBLIC ON ADVANCES IN GENOMIC SCIENCE, SPONSORED BY THE NEW YORK CITY COMMUNITY TRUSTPYEWACKET FUND. THE CENTER HOSTED "FIVE POINTS" LECTURES FOR THE SCIENTIFIC COMMUNITY, FEATURING LEADING RESEARCHERS FROM AROUND THE COUNTRY AND ABROAD. IN ADDITION, NYGC HELD WELL-ATTENDED WORKSHOPS FOR THE MEDICAL COMMUNITY ON SINGLE CELL GENOMICS, EPIGENOMICS, SEQUENCING INFORMATICS AND ANCESTRY. JLABS PARTNERSHIP IN JANUARY 2017, NYGC, JOHNSON & JOHNSON INNOVATION LLC AND NEW YORK STATE ANNOUNCED A COLLABORATION TO LAUNCH A NEW "JLABS" INCUBATOR IN NEW YORK CITY. CALLED "JLABS@NYCSCHEDULED TO OPEN IN SUMMER 2018, THE 30,000-SQUARE FOOT FACILITY ON THE THIRD FLOOR OF NYGC WILL HOUSE AS MANY AS 30 BIOTECH, PHARMACEUTICAL, MEDICAL DEVICE OR CONSUMER AND DIGITAL HEALTH COMPANIES. THE NEW ALLIANCE WAS FORGED TO SUPPORT THE GROWTH OF HEALTH CARE SOLUTIONS IN THE REGION BY PROVIDING A COMPREHENSIVE COMMERCIALIZATION VEHICLE FOR EMERGING LIFE SCIENCE COMPANIES. JLABS SUPPORT OF TALENTED SCIENTISTS IN THE CITY AS THEY TAKE THEIR INNOVATIVE IDEAS TO MARKET ALIGNS WITH NYGCS MISSION OF FOSTERING INTELLECTUALLY VIBRANT COLLABORATIONS THAT ADVANCE THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS AGAINST HUMAN DISEASE. ORGANIZATION MEMBERS FORM 990, PART VI, SECTION A, LINE 6: AS OF DECEMBER 31, 2017, THE CENTER HAD A TOTAL OF 18 MEMBERS, CONSISTING OF 12 INSTITUTIONAL FOUNDING MEMBERS, FIVE ASSOCIATE MEMBERS, AND ONE FOUNDING TECHNOLOGY MEMBER. *THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) THE JACKSON LABORATORY, (4) MEMORIAL SLOAN-KETTERING CANCER CENTER, (5) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (6) NEW YORK-PRESBYTERIAN HOSPITAL, (7) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (8) NORTHWELL HEALTH, (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (10) THE ROCKEFELLER UNIVERSITY, (11) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (12) ALBERT EINSTEIN COLLEGE OF MEDICINE. *ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, (3) THE NEW YORK STEM CELL FOUNDATION, AND (4) ROSWELL PARK CANCER INSTITUTE. (5) PRINCETON UNIVERSITY *FOUNDING TECHNOLOGY MEMBER: (1) INTERNATIONAL BUSINESS MACHINES (IBM) ORGANIZATION MEMBERS - DECISION MAKING FORM 990, PART VI, SECTION A, LINE 7A & 7B: EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGCS BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR AND OTHER DESIGNATED DIRECTORS OR INDIVIDUALS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS. FORM 990 REVIEW FORM 990, PART VI, SECTION B, LINE 11: THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE DIRECTOR OF FINANCE, GENERAL COUNSEL, AND PRESIDENT, REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT WILL MAKE THE FORM 990 AVAILABLE TO THE BOARD OF DIRECTORS. CONFLICT OF INTEREST POLICY & REVIEW FORM 990, PART VI, SECTION B, LINE 12C: NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, PRINCIPAL OFFICERS, OR MEMBERS OF A COMMITTEE IN WHICH THE BOARD HAS DELEGATED POWERS) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY MAKE A PRESENTATION AT THE BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. COMPENSATION REVIEW AND APPROVAL FORM 990, PART VI, SECTION B, LINE 15: FOR THE ORGANIZATIONS TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR PROCESS OF DETERMINING COMPENSATION. FOR ROBERT DARNELL, THE EXECUTIVE LEADERSHIP OF THE BOARD REVIEWED AND APPROVED HIS 2017 CONSULTING FEE. NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT IN LATE 2016 TO REVIEW SENIOR MANAGEMENTS COMPENSATION. RESULTS OF THIS REVIEW WERE PROVIDED TO THE AD-HOC COMPENSATION COMMITTEE IN EARLY 2017. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT WAS REASONABLE, AND THAT MERIT INCREASES FOR 2017 WERE REASONABLE AND APPROPRIATE. SENIOR MANAGEMENT EMPLOYED FOR MORE THAN 18 MONTHS RECEIVED A 4.5% MERIT INCREASE. SENIOR MANAGEMENT EMPLOYED FOR GREATER THAN ONE YEAR BUT LESS THAN 18 MONTHS RECEIVED A 3% MERIT INCREASE. THE PRESIDENT & COO DECLINED A MERIT INCREASE AND HER COMPENSATION WAS UNCHANGED. FORM 990, PART VII, LINE 40(B): DR. ROBERT DARNELL PROVIDED REGULAR CONSULTING SERVICES TO NYGC UNDER A CONSULTANT CONTRACT EXECUTED IN JANUARY 2017. THOSE CONSULTANCY HOURS ARE NOT REFLECTED IN LINE 40(B). DOCUMENT DISCLOSURE FORM 990, PART VI, SECTION C, LINE 19: NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.